Trevi Therapeutics (TRVI) Operating Leases (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Operating Leases came in at $364000.0 in Q1 2026, down 46.55% year-on-year from $681000.0 in Q1 2025, and down 18.39% quarter-over-quarter from $446000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Operating Leases (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Operating Leases history runs 9 years deep, the most recent figure standing at $364000.0 for Q1 2026.
- On a quarterly basis, Operating Leases fell 46.55% year-over-year to $364000.0 in Q1 2026; TTM through Mar 2026 was $364000.0, a 46.55% decrease from a year earlier, with the FY2025 full-year figure at $446000.0, down 40.29% from the prior year.
- Operating Leases slipped to $364000.0 in Q1 2026 per TRVI's latest filing, from $446000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.1 million in Q1 2023 and bottomed at $2000.0 in Q3 2022.
- The 5-year median for Operating Leases is $714000.0 (2024), against an average of $645375.0.
- Across the five-year window, Operating Leases tumbled 96.7% in 2022 and jumped 52450.0% in 2023, its largest moves.
- Year by year, Operating Leases stood at $2000.0 in 2022, then surged by 49950.0% to $1.0 million in 2023, then slipped by 25.37% to $747000.0 in 2024, then slumped by 40.29% to $446000.0 in 2025, then dropped by 18.39% to $364000.0 in 2026.
- Per Business Quant, the three latest TRVI Operating Leases figures stand at $364000.0 (Q1 2026), $446000.0 (Q4 2025), and $527000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364,000.00 |
| Dec 31, 2025 | 446,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 605,000.00 |
| Mar 31, 2025 | 681,000.00 |
| Dec 31, 2024 | 747,000.00 |
| Sep 30, 2024 | 816,000.00 |
| Jun 30, 2024 | 884,000.00 |
| Mar 31, 2024 | 949,000.00 |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Dec 31, 2021 | 24,000.00 |
| Sep 30, 2021 | 58,000.00 |
| Jun 30, 2021 | 91,000.00 |
| Mar 31, 2021 | 123,000.00 |